Spatial Transcriptomics-based Identification of Molecular Markers for Nanomedicine Distribution in Tumor Tissue

To elucidate the factors that determine nanomedicine tumor uptake, we developed a molecular marker identification platform by integrating microscopic fluorescence images of nanomedicine distribution with spatial transcriptomics (ST) information. When this approach is applied to PEGylated liposomes, molecular markers related to hypoxia, glucose metabolism and apoptosis can be identified as being related to the intratumoral distribution of the nanomedicine. We expect that our method can be applied to explain the distribution of a wide range of nanomedicines, and furthermore, the data obtained from this analysis can be used in precise utilization of the nanomedicine. Overall design: Examination of a spatial transcriptomics library generated with the 10x Genomics visium platform and the corresponding fluorescence drug map of a 4T1 solid tumor.